The dissolution of the links between the two Swiss pharmaceutical groups Roche and Novartis is fixed. The Roche shareholders with voting rights voted at an Extraordinary General Meeting for the steps required to acquire almost a third of Roche’s bearer shares from Novartis. Among other things, the shareholders approved the capital reduction by destroying the bearer shares to be repurchased by Novartis with 99.85 percent. The repurchase transaction is expected to be completed in early December 2021. “Today’s decision by the Annual General Meeting is in the best economic and strategic interests of Roche,” said Roche President Christoph Franz. Roche is paying around 19 billion Swiss francs for the share package.
Novartis – Roche buys back shares – Economy
